- Home
- ENTX vs KUKE Comparison
ENTX vs KUKE Comparison
Compare ENTX & KUKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- KUKE
- Stock Information
- Founded
- ENTX 2010
- KUKE 2002
- Country
- ENTX Israel
- KUKE China
- Employees
- ENTX 21
- KUKE N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- KUKE Other Consumer Services
- Sector
- ENTX Health Care
- KUKE Real Estate
- Exchange
- ENTX Nasdaq
- KUKE Nasdaq
- Market Cap
- ENTX 82.2M
- KUKE 86.8M
- IPO Year
- ENTX 2018
- KUKE 2021
- Fundamental
- Price
- ENTX $1.85
- KUKE $1.58
- Analyst Decision
- ENTX Strong Buy
- KUKE
- Analyst Count
- ENTX 1
- KUKE 0
- Target Price
- ENTX $10.00
- KUKE N/A
- AVG Volume (30 Days)
- ENTX 76.7K
- KUKE 33.8K
- Earning Date
- ENTX 11-07-2025
- KUKE 10-15-2025
- Dividend Yield
- ENTX N/A
- KUKE N/A
- EPS Growth
- ENTX N/A
- KUKE N/A
- EPS
- ENTX N/A
- KUKE N/A
- Revenue
- ENTX $166,000.00
- KUKE $9,442,397.00
- Revenue This Year
- ENTX N/A
- KUKE N/A
- Revenue Next Year
- ENTX N/A
- KUKE N/A
- P/E Ratio
- ENTX N/A
- KUKE N/A
- Revenue Growth
- ENTX 191.23
- KUKE N/A
- 52 Week Low
- ENTX $1.50
- KUKE $1.45
- 52 Week High
- ENTX $2.79
- KUKE $16.00
- Technical
- Relative Strength Index (RSI)
- ENTX 42.76
- KUKE 38.23
- Support Level
- ENTX $1.83
- KUKE $1.60
- Resistance Level
- ENTX $2.22
- KUKE $2.04
- Average True Range (ATR)
- ENTX 0.11
- KUKE 0.17
- MACD
- ENTX -0.02
- KUKE 0.02
- Stochastic Oscillator
- ENTX 9.52
- KUKE 14.95
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.